BIO Is Helping Companies Boost Minority Participation In Clinical Trials
Executive Summary
BIO head Michelle McMurry-Heath discusses group’s efforts to increase enrollment of people of color in COVID-19 clinical trials and why New York’s task force to give second review to COVID-19 vaccines is “dangerous for patients.”
You may also be interested in...
Quick BIO CEO Departure Raises Questions About Direction For Next Leadership Pick
Michelle McMurry-Heath brought a science and regulatory background to the top post of the industry trade group in contrast to the political and lobbying focused careers of her predecessors. Her eventual successor may offer hints as to whether BIO thought that was a successful leadership strategy.
Reducing Clinical Trial Burdens Brings Greater Participant Diversity – PhRMA
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.
COVID-19 Vaccines Blaze New Path In the History Of Vaccine Development
Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.